Search Results - Laurie Sherman
- Showing 1 - 6 results of 6
-
1
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors by Geoffrey I. Shapiro, Stewart W. McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, S. Swann, Harold Keer, Dale Miles, Thomas Müller, Daniel C. Rabe, Franco Cecchi, Donald P. Bottaro, Patricia LoRusso
Published 2015Errata/Corrigenda -
2
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 by Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock‐Bryan, Laurie Sherman, Stewart W. McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia LoRusso
Published 2010Artigo -
3
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study by Dirk Schadendorf, Mayur M. Amonkar, Mohammed Milhem, Karen R. Grotzinger, Lev Demidov, Piotr Rutkowski, Claus Garbe, Reinhard Dummer, Jessica C. Hassel, Pascal Wolter, Peter Mohr, Uwe Trefzer, Claudia Lefeuvre‐Plesse, Annemie Rutten, Neil Steven, Gustav Ullenhag, Laurie Sherman, Frank Wu, Kirtan Patel, Michelle Casey, Caroline Robert
Published 2014Artigo -
4
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study by David P. Steensma, Pierre Fenaux, Koen Van Eygen, Azra Raza, Valeria Santini, Ulrich Germing, Patricia Font, María Díez‐Campelo, Sylvain Thépot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Helen Varsos, Jacqueline Bussolari, Esther Rose, Laurie Sherman, Libo Sun, Ying Wan, Souria Dougherty, Fei Huang, Faye Feller, Aleksandra Rizo, Uwe Platzbecker
Published 2020Artigo -
5
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma by Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Brigitte Dréno, Marta Nyakas, Mark R. Middleton, Jürgen C. Becker, Michelle Casey, Laurie Sherman, Frank Wu, Danièle Ouellet, Anne‐Marie Martin, Kiran Klaus Patel, Dirk Schadendorf
Published 2012Artigo -
6
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma by Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan
Published 2012Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Oncology
Gastroenterology
Adverse effect
Chemotherapy
Phases of clinical research
Biology
Cancer
Cell biology
Clinical trial
Kinase
MAPK/ERK pathway
Mucositis
Nausea
Pharmacodynamics
Pharmacokinetics
Pharmacology
Response Evaluation Criteria in Solid Tumors
Trametinib
Urology
Anemia
Aplastic anemia
Biochemistry
Biomarker
Bone marrow
Cancer research
Chemistry
Chemotherapy regimen
Clear cell renal cell carcinoma